Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality

Jean Ching-Yi Tien,Yu Chang,Yuping Zhang,Jonathan Chou,Yunhui Cheng,Xiaoju Wang,Jianzhang Yang,Rahul Mannan,Palak Shah,Xiao-Ming Wang,Abigail J. Todd,Sanjana Eyunni,Caleb Cheng,Ryan J. Rebernick,Lanbo Xiao,Yi Bao,James Neiswender,Rachel Brough,Stephen J. Pettitt,Xuhong Cao,Stephanie J. Miner,Licheng Zhou,Yi-Mi Wu,Estefania Labanca,Yuzhuo Wang,Abhijit Parolia,Marcin Cieslik,Dan R. Robinson,Zhen Wang,Felix Y. Feng,Christopher J. Lord,Ke Ding,Arul M. Chinnaiyan

DOI: https://doi.org/10.1101/2024.03.20.585990

2024-03-21

Abstract:Biallelic loss of cyclin-dependent kinase 12 ( ) defines a unique molecular subtype of metastatic castration-resistant prostate cancer (mCRPC). It remains unclear, however, whether loss is sufficient to drive prostate cancer development—either alone, or in the context of other genetic alterations—and whether -mutant tumors exhibit sensitivity to specific pharmacotherapies. Here, we demonstrate that tissue-specific ablation is sufficient to induce preneoplastic lesions and robust T cell infiltration in the mouse prostate. Allograft-based CRISPR screening demonstrated that loss is positively associated with inactivation but negatively associated with inactivation—akin to what is observed in human mCRPC. Consistent with this, ablation of in prostate organoids with concurrent loss promotes their proliferation and ability to form tumors in mice, while knockout in the -null prostate cancer mouse model abrogates tumor growth. Bigenic and loss allografts represent a new syngeneic model for the study of androgen receptor (AR)-positive, luminal prostate cancer. Notably, loss prostate tumors are sensitive to immune checkpoint blockade. -null organoids (either with or without co-ablation) and patient-derived xenografts from tumors with inactivation are highly sensitive to inhibition or degradation of its paralog kinase, CDK13. Together, these data identify as a tumor suppressor gene with impact on tumor progression and lends support to paralog-based synthetic lethality as a promising strategy for treating mutant mCRPC.

Cancer Biology

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on the following aspects:

1. **Determining the role of CDK12 in the development of prostate cancer**:
- Researchers attempt to clarify whether biallelic inactivation of the CDK12 gene is sufficient to drive the development of prostate cancer, especially in the context of other genetic alterations.
- Specifically, researchers observe the impact on prostate tissue, including whether it will lead to pre - cancerous lesions and T - cell infiltration, through a mouse model with tissue - specific knockout of the CDK12 gene.

2. **Exploring the drug sensitivity of CDK12 - mutated tumors**:
- Researchers explore whether CDK12 - mutated tumors are sensitive to specific drug treatments, especially the inhibition or degradation of its homologous kinase CDK13.
- Through CRISPR screening and mouse model experiments, researchers evaluate the interaction between CDK12 deletion and p53 inactivation, and how these changes affect tumor growth and drug response.

3. **Establishing a new prostate cancer model**:
- Researchers develop a new allograft model (Cdk12/Trp53 double - gene knockout) for studying androgen receptor (AR) - positive luminal prostate cancer.
- This model not only exhibits T - cell - dominated immune infiltration but is also highly sensitive to immunotherapy with immune checkpoint inhibitors.

4. **Investigating the impact of CDK12 deletion on PTEN - inactivated tumors**:
- Researchers find that CDK12 deletion can slow down tumor progression driven by PTEN inactivation, which is consistent with the mutual exclusivity of CDK12 and PTEN mutations in human prostate cancer.
- Through mouse models and in vitro experiments, researchers verify the protective effect of CDK12 deletion in the context of PTEN inactivation.

In summary, this paper aims to comprehensively explore the mechanism of CDK12 in prostate cancer and its potential treatment strategies, especially the synthetic lethality strategy based on homologous kinases, through a variety of experimental means. These research results provide important scientific basis for understanding the function of CDK12 and its clinical application in prostate cancer.